Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction and prevent heart failure. Combined with its speed and efficiency, MyoStrain may provide a critical population management tool to help physicians individualize cardiac treatment for at-risk patient populations in cardiology and oncology.
With 80,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 500+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 minutes and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.
We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.
John Funkhouser has extensive experience in healthcare as Chief Executive Officer of four cardiac life sciences companies including CoeurLabs, PharmaNetics, nContact and now, MSI. Before working in healthcare, Mr. Funkhouser worked in banking and venture capital at Chemical Bank Of New York, Wheat First Securities, Crestar Capital and Hillcrest Group. He is a graduate of Princeton University and the Darden School of Business at the University of Virginia.
Dane Carl Andreeff is the current President, Chief Executive Officer and Director at Helius Medical Technologies, Inc., an advanced medical device company focused on improving neurological health and wellness. He is also the founder of Maple Leaf Partners, LLC and Andreeff Equity Advisors, LLC.
In addition to his role as Director at MSI, Andreeff is Director at HDL Therapeutics, a highly innovative medical company that has developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH). He is also on the board at TraceSecurity, LLC, a security company helping to protect and eliminate risk for companies ranging local and community financial institutions to global enterprises.
Randy Hill currently serves as a key business advisor to United Imaging in North America and specializes in consulting innovative companies across the healthcare imaging sector. Hill brings extensive experience in the medical imaging industry and a background in sales in marketing to help position MSI at the forefront of imaging innovation.
Hill has also served as Chief Executive Officer at Siemens Medical, and previously as Chief Operations Officer and VP of Service at Siemens for more than eight years. Prior to that, Hill served six years as Chief Executive Officer and Director at VasoMedical subsidiary, Vaso Diagnostics, a medical technology company ranging a diverse product and service selection, including several diagnostic imaging solutions as well as non-invasive monitoring and therapeutic devices.
Todd Robinson currently serves as CEO/Principal at Southwood Group, L.L.C., with approximately $45 million in revenue and 200 employees. Robinson also serves as Managing Partner for Hanover Ventures, L.L.C., a venture partnership currently holding three primary investments, including Myocardial Solutions, Inc., VazTec, L.L.C. American Nano, L.L.C. Robinson brings in a diverse background and significant operating experience as both a manager and director.
Bob Kay is currently the Managing Member and CEO of Excelleration Partners, which focuses on helping early-stage growth companies accelerate their growth while also excelling at what they do. Kay brings over 40 years of experience of broad-based banking, private equity intermediary, and private business management experience in various fields to help MSI grow commercially as a medical technology.
Kay has taken on many leadership roles in startup, growth phase and turnaround company situations. He was previously CEO and CFO of DrillingInfo, a major technology growth company, and also currently serves on the Board of MSC Income Fund, Inc.
Jeff Barber is a Managing Director with Fennebresque & Co., an investment banking firm where he focuses on technology and healthcare. Barber brings comprehensive experience to help MSI navigate the business of healthcare and medical technology.
Barber was previously in charge of PricewaterhouseCoopers technology practice in the Carolinas, served on the board of directors at PRA Health Sciences, Ply Gem Holdings, Inc., SciQuest Inc., and LipoScience, Inc. He also currently serves on the board of trustees and as chair of the audit committee of Blue Cross Blue Shield of North Carolina, on the board of directors and as past chair of Echo Health Ventures.
Gary Brock brings over 40 years of progressive healthcare executive leadership and governance experience to help propel MSI forward as MyoStrain transitions to becoming a new standard in cardiac care.
Brock has served Baylor Scott & White Health for more than 35 years in numerous leadership positions, including President and Chief Operating Officer of the legacy Baylor Healthcare system, and Chief Integrated Delivery Network Officer. He created one of the largest and top-performing Accountable Care Organizations in Texas and in the nation, focusing on patient-centered care. He also served as a member of the Board of Trustees of the Texas Hospital Association, Austin, Texas and was elected chairman of the board in 2014.
Memorial MRI & Diagnostic (MMD) has partnered with Myocardial Solutions to build Houston's first and only MyoStrain Cardiac Prevention Center in Katy, Texas. MMD's longstanding commitment towards improving the lives of patients through its line of state-of-the-art imaging technologies and community-focused services has made MMD the ideal caliber of outpatient imaging facilities to offer MyoStrain. With more than 10 locations spread across Greater Houston, Dallas, Beaumont, Corpus Christi and surrounding cities, the partnership will deliver the unique MyoStrain MRI heart scan to communities throughout Texas, expanding access to better cardiac care and helping patients take control of their heart health.
"We are incredibly excited to offer MyoStrain at our Katy facility, as the prevalence and risk of cardiac diseases within our community is exceedingly high. In addition to providing a uniquely accurate assessment of heart health, MyoStrain also gives us the speed and efficiency to address large at-risk patient populations. We believe it is a vital solution to help our community’s care providers proactively manage heart health while supporting the enormous volume of patients in need of cardiac care.”
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has partnered with Myocardial Solutions Inc. to bring rapid cardiac MR imaging to unmet cancer care and cardiology markets, helping enable physicians to protect and manage patient heart health during and after cancer treatment.
United Imaging is the preferred provider for MyoStrain®, and the two companies have joined together to deliver this dedicated solution to cancer centers and hospitals. The FDA’s 510(k) pre-market clearance of MyoStrain for United Imaging MRI machines marks the availability of this novel, proprietary technology in the U.S. market.
“With this joint solution from Myocardial Solutions and United Imaging, oncologists and cardiologists will be able to monitor patient heart health before, during, and after cancer treatment. Together, United Imaging and Myocardial Solutions will deliver the diagnostic testing using MyoStrain software on a dedicated MR scanner for both cancer centers and cardiologists. The fast, MR based technique is highly automated to deliver reproducible results.”
Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction and prevent heart failure. Combined with its speed and efficiency, MyoStrain may provide a critical population management tool to help physicians individualize cardiac treatment for at-risk patient populations in cardiology and oncology.
With 80,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 500+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 minutes and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.
We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.
